Zsa Zsa Weerts

TRP channels as therapeutic targets in IBS 101 4 meta-analysis. J Clin Gastroenterol 2014;48:505-512. 92. Amato A, Liotta R, Mule F. Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action. Eur J Pharmacol 2014;740:295-301. 93. Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 2016;61:560-571. 94. Tack J, Schumacher K, Tonini G, et al. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut 2016;DOI 10.1136/gutjnl-2015-310683. 95. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69:1853-1878. 96. Laird J. Gut feelings about tachykinin NK1 receptor antagonists. Trends Pharmacol Sci 2001;22:169. 97. Hill R. NK1 (substance P) receptor antagonists--why are they not analgesic in humans? Trends Pharmacol Sci 2000;21:244- 246. 98. Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993;265:G742-751. 99. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994;268:1206-1211. 100. Bradette M, Delvaux M, Staumont G, et al. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171-1178. 101. Mulak A, Larauche M, Biraud M, et al. Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice Peptides 2015;63:71-80. 102. Sullenger BA, Nair S. From the RNA world to the clinic. Science 2016;352:1417-1420. 103. Pereira LM, Lima-Junior RC, Bem AX, et al. Blockade of TRPA1 with HC-030031 attenuates visceral nociception by a mechanism independent of inflammatory resident cells, nitric oxide and the opioid system. Eur J Pain 2013;17:223-233. 104. Kojima R, Nozawa K, Doihara H, et al. Effects of novel TRPA1 receptor agonist ASP7663 in models of drug-induced constipation and visceral pain. Eur J Pharmacol 2014;723:288- 293. 105. Preti D, Saponaro G, Szallasi A. Transient receptor potential ankyrin 1 (TRPA1) antagonists. Pharm Pat Anal 2015;4:75-94. 106. Willette RN, Bao W, Nerurkar S, et al. Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2. J Pharmacol Exp Ther 2008;326:443- 452. 107. Szallasi A, Sheta M. Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opin Investig Drugs 2012;21:1351-1369. 108. Lehto SG, Tamir R, Deng H, et al. Antihyperalgesic effects of (R,E)-N-(2- hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2- (piperidin-1-yl)-4-(trifluorom ethyl)phenyl)- acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008;326:218-229. 109. Meissner M, Obmann VC, Hoschke M, et al. Lessons of Studying TRP Channels with Antibodies. In TRP Channels (Zhu, M.X. (ed.)). Boca Raton (FL), 2011. 110. Alexander SP, Catterall WA, Kelly E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. Br J Pharmacol 2015;172:5904-5941. 111. Blackshaw LA. Transient receptor potential cation channels in visceral sensory pathways. Br J Pharmacol 2014;171:2528-2536. 112. Vriens J, Appendino G, Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009;75:1262-1279.